Is that how Tonix Pharmaceuticals (TNXP) surged in the Premarket today?

DPRO Stock
DPRO Stock

Tonix Pharmaceuticals Holding Corp. (TNXP) shares go up more than 28% to $0.849 in the ‎premarket trading session after it revealed the closing of the purchase of a 44-acre site in ‎Hamilton, Montana, that will be used to develop and manufacture vaccines. In September ‎‎2020, Tonix entered into a lease agreement to purchase 40,000 square feet in ‎Massachusetts to house their new Advanced Development Center for accelerated testing of ‎vaccines for clinical trials.‎

Get the hottest stocks to trade ‎every day before the market opens 100% ‎free. Click here now. 

‎The Montana and Massachusetts facilities are also planned to promote the production and ‎manufacturing of candidate Tonix vaccines provided by adapted horsepox vaccines, TNX-‎‎1800, a possible COVID-19 vaccine, and TNX-801, a potential vaccine for smallpox and ‎monkeypox.‎

Top 5 EV Tech Stocks to Buy for 2023

The electric vehicle boom is accelerating – and fast. According a new report published by BloombergNEF, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now. Get our free report, "Top 5 EV Tech Stocks to Buy for 2023".

Click Here to Download the FREE Report.


Read More

Tonix Pharmaceuticals is currently working on COVID-19 vaccines using two live viral vector ‎platforms, horsepox and bovine parainfluenza virus (BPI virus). COVID-19 has four potential ‎vaccines in development based on the horsebox vector and two vaccines based on the BPI ‎vector. The Company’s lead vaccine, TNX-1800, is based on the horsepox vector1. The ‎horsepox virus is thought to be very similar to the smallpox vaccine, which was developed by ‎Dr. Edward Jenner and eradicated smallpox: the only disease ever destroyed. It was recently ‎discovered that horsepox is nearly identical to a vaccine used in the US in the mid-1800s for ‎smallpox2. TNX-1800 is believed to produce a predominantly T cell response to vaccination ‎and to prevent onward transmission. In the first quarter of 2021, Tonix plans to report ‎efficacy data from its animal challenge studies on TNX-1800.‎


Please enter your comment!
Please enter your name here